A total of 868 subjects of which 70% were Chinese and 13% Korean were randomised to once-weekly subcutaneous semaglutide 0.5 mg (n=288), 1.0 mg (n=290) or sitagliptin 100 mg (n=290) in a multiregional clinical trial. Both doses of semaglutide were superior to sitagliptin in reducing HbA1c (primary endpoint, Figure 1) and body weight (Table 1) after 30 weeks of treatment. The odds for achieving target HbA1c, weight loss of ≥5% or ≥10% and a composite endpoint were all significantly higher with both semaglutide doses compared to sitagliptin (Table 1). The safety profile of semaglutide was consistent with the previously established profile. Consistent efficacy and safety findings were seen in the Chinese population.

graphic
View largeDownload slide
graphic
View largeDownload slide
Disclosure

L. Ji: None. D. Xiaolin: None. F. Eliaschewitz: Advisory Panel; Self; AstraZeneca, Novo Nordisk A/S, Sanofi-Aventis. Research Support; Self; Bayer AG, GlaxoSmithKline plc., Novo Nordisk A/S, Sanofi-Aventis. Speaker’s Bureau; Self; Eli Lilly and Company. Y. Li: None. Y. Li: None. S. Lim: None. M. Liu: None. N. Zu: Employee; Self; Novo Nordisk A/S. S. Rasmussen: Employee; Self; Novo Nordisk A/S. T.V. Skjoeth: Employee; Self; Novo Nordisk A/S. G. Yuan: None. Y. Huang: None.

Funding

Novo Nordisk A/S

© 2020 by the American Diabetes Association
2020
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.